Clinical Trials Logo

Recurrent Oral Cavity Squamous Cell Carcinoma clinical trials

View clinical trials related to Recurrent Oral Cavity Squamous Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02388932 Terminated - Clinical trials for Stage IVA Oropharyngeal Squamous Cell Carcinoma

Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Start date: March 3, 2015
Phase: N/A
Study type: Interventional

This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with head and neck cancer that has spread from where it started to nearby tissue or lymph nodes and is at high risk for continuing to spread because the patient cannot undergo standard chemotherapy. Stereotactic body radiation therapy is a specialized radiation therapy that delivers radiation directly to the tumor in smaller doses over several days, which may kill more tumor cells and cause less damage to normal tissue.

NCT ID: NCT01267240 Active, not recruiting - Clinical trials for Stage IVA Oropharyngeal Squamous Cell Carcinoma

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This partially randomized phase II trial studies giving capecitabine and vorinostat in treating patients with head and neck cancer that has come back after previous treatment or that has spread to other areas in the body. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving capecitabine together with vorinostat is more effective than capecitabine alone in treating patients with cancer of the head and neck cancer.